^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pasritamig (JNJ-8343)

    i
    Other names: JNJ-8343, JNJ-78278343, JNJ78278343, JNJ8343, JNJ 78278343, JNJ 8343
    Associations

    News

    Trials
    Company:
    J&J, Zymeworks
    Drug class:
    CD3 agonist, KLK2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    24d
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=177, Recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2028 --> Oct 2027 | Trial primary completion date: Nov 2028 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    24d
    KLK2-PASenger: A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=800, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    docetaxel • prednisone • pasritamig (JNJ-8343)
    2ms
    A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=216, Recruiting, Janssen Research & Development, LLC | Active, not recruiting --> Recruiting | Trial completion date: Feb 2026 --> Feb 2027
    Enrollment open • Trial completion date
    |
    pasritamig (JNJ-8343)
    2ms
    A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=250, Recruiting, Janssen Research & Development, LLC | N=130 --> 250
    Enrollment change
    |
    pasritamig (JNJ-8343)
    2ms
    KLK2-comPAS: A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P3, N=663, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pasritamig (JNJ-8343)
    3ms
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=247, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Aug 2028 --> Nov 2028
    Trial primary completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    3ms
    KLK2-comPAS: A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P3, N=663, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    pasritamig (JNJ-8343)
    3ms
    A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer (clinicaltrials.gov)
    P1, N=245, Recruiting, Janssen Research & Development, LLC | N=176 --> 245
    Enrollment change
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • prednisone • Nubeqa (darolutamide) • cabazitaxel • apalutamide • cetrelimab (JNJ-63723283) • pasritamig (JNJ-8343)
    4ms
    A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer (clinicaltrials.gov)
    P1, N=110, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    JNJ-8177 • pasritamig (JNJ-8343)
    4ms
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=247, Recruiting, Janssen Research & Development, LLC | Trial completion date: Aug 2028 --> Nov 2028
    Trial completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)
    4ms
    A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer (clinicaltrials.gov)
    P1, N=110, Not yet recruiting, Janssen Research & Development, LLC
    New P1 trial
    |
    JNJ-8177 • pasritamig (JNJ-8343)
    5ms
    CR108817: A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=247, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2028 --> Aug 2028 | Trial primary completion date: May 2028 --> Aug 2028
    Trial completion date • Trial primary completion date
    |
    JNJ-6420 • pasritamig (JNJ-8343)